Bristol Myers Squibb reports two-year Sotyktu psoriatic arthritis data

Bristol Myers Squibb (BMY) reported that Sotyktu (deucravacitinib) showed durable efficacy and consistent safety over two years in psoriatic arthritis patients. Key metrics like ACR 20/50/70 and MDA improved and were maintained. The FDA approved Sotyktu for this use in March. BMY shares were down 0.35% to $63.38 at the time of publication.

Bristol Myers Squibb (BMY) reported two-year Phase 3 trial results for Sotyktu, showing sustained efficacy and no new safety signals in adults with psoriatic arthritis. ACR20/50/70 response rates were 76.2%, 52.6%, and 34.6% at Week 104 for continuous treatment. The company plans to present full results at upcoming medical conferences.

Bristol Myers Squibb (BMY) reported two-year data from the POETYK PsA-2 study, showing durable efficacy and consistent safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. ACR20/50/70 response rates at Week 104 were 76.2%/52.6%/34.6% (observed) and 65.3%/44.9%/29.4% (NRI) for continuous Sotyktu treatment. Safety profile remained consistent with no new signals. Results were presented at the Congress of Clinical Rheumatology - West.

Bristol-Myers Squibb (BMY) reported positive Phase 3 trial results for Sotyktu in treating psoriatic arthritis. The company offers a 3.95% dividend yield with a 39% payout ratio and a 4.4% 3-year dividend growth rate. BMY's GF Score is 71, indicating strong profitability but modest growth. Insiders and gurus have shown net selling. The stock trades 12.4% above its GF Value of $56.60.

Bristol-Myers Squibb (BMY) stock has risen 44.4% over the past year. Positive Phase 2 data for arlocabtagene autoleucel in multiple myeloma may influence future cash flows. The company's free cash flow is around $11.5 billion, with projections ranging from $10 billion to $13 billion annually. A discounted cash flow model suggests the stock may be undervalued by 46% at its current price of $63.60, according to Simply Wall St.

Bristol Myers Squibb (BMY) and Ono Pharmaceutical sued Amgen (AMGN) to block its biosimilar version of Opdivo, alleging patent infringement. Opdivo generated $5.9B in U.S. sales last year. Amgen aims to be among the first Opdivo biosimilars, with FDA approval sought.